Stock Events

Stock Events

Lexicon Pharmaceuticals 

$2.25
194
-$0.02-0.88% Thursday 19:59
+$0.01+0.44%Thursday 22:22After hours

Statistics

Day High
2.26
Day Low
2.25
52W High
2.68
52W Low
1
Volume
27,077
Avg. Volume
-
Mkt Cap
999.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.18
-0.12
-0.05
0.01
Expected EPS
-0.050233
Actual EPS
N/A

Financials

-101.08%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
49.8MRevenue
-50.34MNet Income

Analyst Ratings

4.55Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LXRX. It's not an investment recommendation.
Apple
35
AAPL
Tesla
35
TSLA
Microsoft
34
MSFT
Amazon
32
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including cystic fibrosis, where there is some overlap in therapeutic areas with Lexicon.
AMGEN
AMGN
Mkt Cap201.93B
Amgen competes in the biopharmaceutical space, developing drugs that could potentially be in direct competition with Lexicon's pipeline, especially in areas like cardiovascular diseases.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Lexicon's interests, such as liver disease.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with Lexicon in developing drugs for conditions like diabetes and cardiovascular diseases.
Biogen
BIIB
Mkt Cap31.91B
Biogen competes with Lexicon in the biopharmaceutical field, focusing on developing therapies for neurological and neurodegenerative diseases, a potential area of interest for Lexicon.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie operates in similar therapeutic areas as Lexicon, including immunology and oncology, making it a direct competitor in the pharmaceutical market.
Merck
MRK
Mkt Cap319.99B
Merck & Co. is a global healthcare company that competes with Lexicon through its broad range of prescription medicines, vaccines, biologic therapies, and animal health products.
Pfizer
PFE
Mkt Cap138.61B
Pfizer is a direct competitor due to its extensive range of healthcare products that could compete with Lexicon's drug pipeline in various therapeutic areas.
Novartis
NVS
Mkt Cap305.1B
Novartis competes with Lexicon in the pharmaceutical and biotechnology industry, focusing on a wide range of therapeutic areas, including those targeted by Lexicon.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Lexicon in developing innovative medicines in oncology, cardiovascular, renal & metabolism, and respiratory diseases.

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Show more...
CEO
Dr. Michael S. Exton Ph.D.
Employees
103
Country
United States
ISIN
US5288723027

Listings

XNAS
US
LXRX
MU
DE
LX31.MU
BOATS
BOATS
LXRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Lexicon Pharmaceuticals stock price today?▼
The current price of LXRX is $2.25 USD — it has decreased by -0.88% in the past 24 hours. Watch Lexicon Pharmaceuticals stock price performance more closely on the chart.
What is Lexicon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Lexicon Pharmaceuticals stocks are traded under the ticker LXRX.
Is Lexicon Pharmaceuticals stock price growing?▼
LXRX stock has fallen by -3.02% compared to the previous week, the month change is a +19.68% rise, over the last year Lexicon Pharmaceuticals has showed a +99.12% increase.
What is Lexicon Pharmaceuticals market cap?▼
Today Lexicon Pharmaceuticals has the market capitalization of 999.44M
When is the next Lexicon Pharmaceuticals earnings date?▼
Lexicon Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What were Lexicon Pharmaceuticals earnings last quarter?▼
LXRX earnings for the last quarter are 0 USD per share, whereas the estimation was -0.03 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lexicon Pharmaceuticals revenue for the last year?▼
Lexicon Pharmaceuticals revenue for the last year amounts to 49.8M USD.
What is Lexicon Pharmaceuticals net income for the last year?▼
LXRX net income for the last year is -50.34M USD.
How many employees does Lexicon Pharmaceuticals have?▼
As of July 10, 2026, the company has 103 employees.
In which sector is Lexicon Pharmaceuticals located?▼
Lexicon Pharmaceuticals operates in the Health & Wellness sector.
When did Lexicon Pharmaceuticals complete a stock split?▼
The last stock split for Lexicon Pharmaceuticals was on May 21, 2015 with a ratio of 1:7.
Where is Lexicon Pharmaceuticals headquartered?▼
Lexicon Pharmaceuticals is headquartered in The Woodlands, United States.